Omeros Corporation (NASDAQ:OMER) Receives $18.00 Average Price Target from Brokerages

Omeros Corporation (NASDAQ:OMERGet Free Report) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $18.00.

OMER has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of Omeros in a research report on Tuesday, June 10th. They issued a “buy” rating and a $9.00 price objective on the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, May 16th.

Check Out Our Latest Research Report on OMER

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after buying an additional 95,599 shares during the period. Nomura Holdings Inc. increased its position in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after buying an additional 430,932 shares during the period. Two Sigma Investments LP grew its holdings in Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after purchasing an additional 13,201 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock valued at $1,242,000 after purchasing an additional 3,321 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Omeros during the fourth quarter valued at approximately $1,488,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Down 0.3%

Omeros stock opened at $3.21 on Monday. The firm has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $7.39. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The company has a market capitalization of $188.07 million, a PE ratio of -1.21 and a beta of 2.21.

Omeros (NASDAQ:OMERGet Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). As a group, equities analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

About Omeros

(Get Free Report

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Featured Stories

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.